Sanjivani Vati: Traditional Uses, Evidence & Safety

TL;DR

Sanjivani vati is a classical Ayurvedic tablet used for digestive complaints, fever, and "ama" (metabolic residue) conditions. The only clinical study found is a 2021 single-arm open pilot: 40 IBS-D patients took Sanjivani vati plus Lashunadi vati for 60 days and reported significant symptom improvement. With no control group and a two-drug combination, the study cannot isolate Sanjivani vati's effect.

What it is

Sanjivani vati is a classical vati (tablet) formulation referenced in Ayurvedic texts including Sharangadhara Samhita, traditionally prepared from ingredients such as vidanga, shunthi, pippali, haritaki, bibhitaki, amalaki, vacha, guduchi, and bhallataka, processed with gomutra (cow urine). It belongs to the deepana-pachana category: formulas intended to kindle digestive fire and clear ama.

Traditional use

Classical indications center on ajirna (indigestion), atisara (diarrhea), jvara with ama (fever complicated by digestive sluggishness), and gulma-type abdominal complaints. Folk and clinical Ayurvedic practice also employs it more broadly as a "reviving" (sanjivani = life-restoring) formula. These are traditional claims, not clinical proof.

What modern research says

Open pilot in diarrhea-predominant IBS

In a single-arm open pilot at the All India Institute of Ayurveda, 40 patients with Rome-III-defined IBS-D received Sanjivani vati (125 mg twice daily) plus Lashunadi vati (500 mg twice daily) for 60 days. Abnormal stool form, bowel frequency, abdominal pain, bloating, mucus, and incomplete evacuation all improved significantly (p ≤ 0.05), with no adverse events and no symptom recurrence at one-month follow-up. Because there was no control group and two drugs were given together, the study cannot show that Sanjivani vati itself caused the improvement. Placebo and natural fluctuation can't be ruled out either (single-arm open pilot, n=40, combination therapy) (Kapoor, Journal of Ayurveda and Holistic Medicine, 2021).

Dry-gangrene case report (multimodal)

A published case report described integrative management of dry gangrene in which Sanjivani vati was one component of a multimodal Ayurvedic regimen. The outcome was reported as favorable, but a single case with multiple simultaneous treatments cannot establish that any one component worked (case report) (PMC6891997).

What the evidence does not support (yet)

No controlled trial supports Sanjivani vati for IBS, diarrhea, indigestion, or gangrene. The IBS pilot's design (no control, combination therapy) means its positive result is hypothesis-generating at best. Do not read it as proof the tablet works.

Safety & contraindications

The pilot reported no adverse events over 60 days, but 40 patients in an open study cannot establish safety. Classical Sanjivani vati contains bhallataka (Semecarpus anacardium), a potent and potentially toxic ingredient that requires proper classical processing; improperly prepared products may cause skin and mucosal irritation. Do not use Sanjivani vati for bloody diarrhea, gangrene, or any serious condition instead of urgent medical care. Avoid during pregnancy and lactation on precautionary grounds, and keep away from children.

FAQs

Does Sanjivani vati work for IBS?

One small open pilot of a two-drug combination reported improvement, but without a control group it proves nothing. Proper randomized trials are needed.

What is Lashunadi vati, the other drug in the study?

A classical garlic-centered tablet for digestive complaints. The study tested the pair together, so neither drug's individual effect is known.

Is it safe for long-term use?

Unknown. The only safety observation is 40 patients over 60 days with no reported adverse events, which is far too little to judge long-term safety.

Why does this article mention bhallataka?

Because classical Sanjivani vati includes it, and it is a known irritant/toxicant when improperly processed. Product quality matters enormously with this formula.

Sources

Single-arm open pilot of Sanjivani vati plus Lashunadi vati in 40 IBS-D patients, reporting symptom improvement without a control group: Kapoor, JAHM 2021.

Case report of multimodal Ayurvedic management of dry gangrene including Sanjivani vati: PMC6891997.

Disclaimer

Sanjivani vati has no controlled-trial evidence for any condition. Do not use it for gangrene, bloody diarrhea, or serious illness instead of urgent medical care, and be aware that classical formulas may contain potent ingredients requiring proper manufacture. This article is educational, not medical advice.